Over 50,000 people are diagnosed with a myeloid neoplasm every year in the U.S. alone. A high-risk subset of these patients is unresponsive to current treatments and their survival is less than a year, a rate that has remained unchanged for the last 40 years. The long-term goal of our work is to improve the outcome for these patients. To accomplish this, research in the lab focuses on understanding the underlying genomic abnormalities in high-risk myeloid neoplasms, to identify new treatment options.
We use a variety of next-generation approaches to decipher the cancer genome.